Benzinga·2025-10-20 09:10分组1 - Delcath Systems Inc reported a significant increase in share price, rising 14.2% to $13.66 in pre-market trading following the announcement of preliminary third quarter 2025 financial results [1] - The company's Phase 2 CHOPIN study achieved its primary endpoint, demonstrating that PHP plus immunotherapy extended median progression-free survival (PFS) to 12.8 months, compared to 8.3 months previously [1] 分组2 - Beyond Meat Inc saw a substantial gain of 76.6%, reaching $1.14 in pre-market trading after a 24% surge on the previous Friday [4] - FGI Industries Ltd experienced a 64.1% increase to $7.81 in pre-market trading [4] - Celcuity Inc surged 44.3% to $75.00 following the announcement of Phase 3 VIKTORIA-1 data [4] - Rani Therapeutics Holdings Inc's shares jumped 32.5% to $2.18 after a collaboration agreement with Chugai Pharmaceutical and an oversubscribed $60.3 million private placement [4] 分组3 - Exelixis Inc's shares fell 8.3% to $36.00 after announcing detailed results from the Phase 3 STELLAR-303 trial evaluating zanzalintinib in combination with an immune checkpoint inhibitor in metastatic colorectal cancer [5]